Compare Ralph Lauren Corp (RL) vs Stryker Corporation (SYK) Price & Performance

Ralph Lauren (RL) trades at $361.14, down 2.04% on the day, amid a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue and net income have grown steadily, reaching $7.08 billion and $743 million in 2025, respectively, while profitability metrics like a 70.27% gross margin and 37.54% ROE highlight operational strength. Analyst sentiment remains bullish with a consensus price target of $456.67, though technical indicators show near-term resistance at $363.

The outlook for RL is positive based on fundamental growth and analyst support, but investors face risks from market volatility and execution challenges. The stock's current valuation at a P/E of 23.15 appears reasonable given earnings momentum, yet competitive pressures and macroeconomic factors could limit upside. Institutional confidence is high, with 66.67% of analysts rating it a buy, suggesting potential for appreciation if the company maintains its earnings trajectory.

Stryker Corporation (SYK) trades at $275.40, down 1.11% amid bearish technical signals and recent negative news regarding manufacturing issues. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $3.69 versus $3.49 expected, and profitability metrics remain robust with a 14.43% net income margin. Analyst consensus remains overwhelmingly bullish with a $368.11 price target representing 33% upside potential.

Despite near-term headwinds from manufacturing disclosures and legal investigations, Stryker's solid earnings track record, strong cash flow generation, and dominant medical technology position support long-term growth prospects. Key risks include ongoing legal scrutiny and competitive pressures in the medtech sector.